Multiple Sclerosis Journal · 1999 · 130 citations · 14 references
EducationNeurologyDisability InsuranceDisability ManagementPhysical DisabilitiesDisability AssessmentDisability DataDisability EvaluationDisability StatisticsMobility ImpairmentMultiple SclerosisAccess To Full-time EmploymentDisability Status AnalysisDisability Status DeterminationEarly Intervention InclusionPatient Registry RecruitmentProgressive Disease AssessmentProgressive Disease Quantification
We have obtained a current profile of multiple sclerosis York State through a centralized patient registry and standardized data collection instrument associated with the New York State Multiple Sclerosis Consortium of 12 MS centers located throughout the state. Data from the first 3019 patients with clinically definite MS revealed a clear relationship between MS disease type, duration of disease, and severity of physical disability. Patients with relapsing disease had disease durations approximately half as long as those with progressive forms of the disease (means approximately 6 years versus 11 years). The majority of patients with relapsing disease had Expanded Disability Status Scale (EDSS) scores of 4.0 or less (self-sustained, fully ambulatory), whereas the majority of patients with progressive disease types had EDSS scores of 6.0 or greater (at least unilateral assist for walking). These findings emphasize the importance of early intervention in patients with relapsing disease to slow or prevent the accumulation of physical disability associated with progressive types of disease. Progressive disease was associated with lack of full-time employment and being disabled before the age of 60 years. Patients with relapsing disease were more likely to be employed and have private forms of insurance, whereas patients with progressive types of disease were more likely to have government-supported insurance to cover medical expenses.
14
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations
Defining the clinical course of multiple sclerosis
Fred Lublin, Stephen C. Reingold · Neurology · 1996 · 3.7K citations
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Neurology · 1993 · 2.1K citations
Pharmacy, Neurology, Pharmacotherapy +14